Published January 29, 2018 | Version v1
Dataset Open

Optimising C2C12 muscle myoblast transfection with polyethylenimine (PEI) or Lipofectamine-2000

  • 1. Structural Genomics Consortium, University of Oxford

Description

Optimisation of DNA transfection of the C2C12 muscle myoblast cell line, comparing use of polyethylenimine (PEI) and Lipofectamine-2000 with varying treatment conditions. 

Notes

Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.

Files

Optimising_C2C12_transfection_methods_20180129.pdf

Files (978.6 kB)